

Informazione Regolamentata n. 0957-53-2024	Data/Ora Inizio Diffusione 4 Settembre 2024 11:27:58	Euronext Milan
--	---	----------------

Societa' : DIASORIN

Identificativo Informazione
Regolamentata : 195180

Utenza - Referente : DIASORINN01 - Ulisse Spada - Valerio
Giovanni Vaccarone

Tipologia : 3.1

Data/Ora Ricezione : 4 Settembre 2024 11:27:58

Data/Ora Inizio Diffusione : 4 Settembre 2024 11:27:58

Oggetto : Diasorin S.p.A. - Shareholders' Meeting
September 4, 2024

Testo del comunicato

See attachment.

DIASORIN S.P.A. - SHAREHOLDERS' MEETING SEPTEMBER 4, 2024

THE SHAREHOLDERS' MEETING OF DIASORIN S.P.A. HELD TODAY:

- IN ORDINARY SESSION, APPOINTED ERNST & YOUNG S.P.A. AS STATUTORY AUDITOR OF ACCOUNTS FOR THE PERIOD 2025-2033;
- IN EXTRAORDINARY SESSION, APPROVED THE AMENDMENT OF ARTICLES 1 ("COMPANY NAME"), 8 ("SHAREHOLDERS' MEETING"), 9 ("PARTICIPATION IN AND REPRESENTATION AT SHAREHOLDERS' MEETINGS") AND 13 ("MEETINGS OF THE BOARD OF DIRECTORS") OF THE COMPANY'S BYLAWS.

Saluggia (Italy) – September 4, 2024 - Diasorin (FTSE MIB: DIA) informs that the Shareholders' Meeting met today under the chairmanship of Michele Denegri, in ordinary and extraordinary session, attended by shareholders representing 89.403% of the voting rights

The ordinary Shareholders' Meeting appointed in advance Ernst & Young S.p.A. as statutory auditor of accounts for the period 2025-2033, establishing also the relevant fees pursuant to Legislative Decree 39/2010, all the above in line with the motivated opinion drafted by the Board of Statutory auditors, to which please refer for further details.

The extraordinary Shareholders' Meeting approved the proposal to amend articles 1 ("Company Name"), 8 ("Shareholders' Meeting"), 9 ("Participation in and representation at Shareholders' Meetings") and 13 ("Meetings of the Board of Directors") of the Company's bylaws.

In particular, also for the purposes of article IA.2.3.2. of the Instructions for the Regulation of the Markets organized and managed by Borsa Italiana S.p.A., it should be noted that the proposal of amendment to article 1 ("Company name") of the Company's bylaws, approved today by the extraordinary Shareholders' Meeting, consists in the change of the company name to "Diasorin S.p.A."

The new Company's By-Laws, as amended by the today's extraordinary Shareholders' Meeting, will be made available on the Company website www.diasorin.com ("Governance", "Governance Documents", "Bylaws") and also through the authorized storage mechanism eMarketStorage (<https://www.emarketstorage.it>) according to the terms provided by the law.

For further information regarding the aforementioned shareholders' resolutions, reference should be made to the Explanatory Reports presented by the Board of Directors available on the Group's website and to the minutes of the Shareholders' Meeting that will be published within the legal deadline on the Group's website in the section "Company", "Governance", "Shareholders' Meeting", "2024". The summary report on votes will be made available on the company's website ("Company", "Governance", "Shareholders' Meeting", "2024") within the terms set forth by the law.

As Financial Reporting Officer, Piergiorgio Pedron declares - pursuant to paragraph 2, Article 154-bis of Legislative Decree no. 58/1998 - that the accounting information contained in this communication corresponds to the documentary results, books and accounting records.

PRESS RELEASE ○○○

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 39 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:**INVESTOR RELATIONS****Riccardo Fava**

Corporate VP Communication, ESG & Investor Relations
riccardo.fava@diasorin.com

Eugenia Ragazzo

Corporate Investor Relations & ESG Analyst
eugenia.ragazzo@diasorin.com

Fine Comunicato n.0957-53-2024

Numero di Pagine: 4